Science News

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on Monday, June 29, 2026. After the meeting materials are finalized and filed with the Securities and Exchanges Commission, such materials will be mailed to shareholders. The Company also advises its Financial Statements included in its Annual Report o...

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced the presentation of initial clinical data from the first participant dosed in its Phase 1/2 trial of EN-374 for the treatment of X-linked chronic granulomatous disease (X-CGD) at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11-15 in Boston. The data represent the first reported clini...

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Co...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following upcoming investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Format: Fireside chat and one-on-one investor meetings Participants: Roop K. Lakkaraju, Chief Financial Officer Date and Time: Tuesday, May 19, 2026, at 8:30 AM Eastern Time; a live webc...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference Location: Jazz at Lincoln Center’s Frederick P. Rose Hall Date: May 12, 2026 Format: Emerging Company Pavilion, a curated showcase of 8-10 select companies Management: Ozan Pamir, CFO...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the first quarter ended March 31, 2026. Q1 2026 Highlights CyPath® Lung unit sales increased 146% year-over-year in the first quarter of 2026, reflecting accelerating physician adoption and expanding clinical use of the Company’s no...

PRINCETON, N.J.--(BUSINESS WIRE)--Kanvas Biosciences, a full-stack spatial biology and microbial therapeutics company, today announced a new investment from Gates Foundation. Through this investment, Kanvas will develop the world’s first fully synthetic microbiome replacement product designed to treat and prevent maternal environmental enteric dysfunction (EED), a major contributor to maternal undernutrition, low infant birthweight and heightened neonatal health risk. Using global metagenomic d...

SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced the initiation of the KYRON Phase 1b/2 clinical trial of ABS-1230 for the treatment of KCNT1-related epilepsy, a rare, severe and often fatal pediatric developmental epileptic encephalopathy. ABS-1230 is designed to be a potent and selective orally available small molecule KCNT1 inhibitor that addresses the underlying...

LONDON--(BUSINESS WIRE)--Asset Value Investors Limited (“AVI”) today announced an update to its public campaign regarding Rohto Pharmaceutical Co., Ltd. (TSE: 4527, “Rohto”), as a follow-up to its ongoing campaign, “Awakening Rohto”, launched last year and aimed at enhancing the company’s corporate value. AVI has published a detailed presentation on a dedicated website (www.AwakeningRohto.com). Since initiating its investment in June 2024, AVI has sought to engage in constructive dialogue with...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that its board of directors authorized the repurchase of an additional $2 billion of IQVIA’s common stock under IQVIA’s existing equity repurchase program (the “Repurchase Program”), bringing the total remaining authorization to $3.2 billion...